title: Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
abstract: BACKGROUND
  The aim of this study was to examine the effect of proton-pump inhibitor (PPI) on clinical outcomes in Japanese patients who undergo coronary stent implantation.
  
  
  RESULTS
  A total of 1,270 patients (males 915, 69 years) were enrolled and dual antiplatelet therapy of aspirin and a thienopyridine derivative was prescribed (clopidogrel 630, ticlopidine 640). Patients were divided into 2 groups treated with or without PPI. PPI was administered in 331 cases (26%), and non-PPI in 939 (74%). There were no significant differences in cardiovascular death (PPI vs. non-PPI: 5 vs. 11 cases), nonfatal myocardial infarction (3 vs. 5), and stroke (3 vs. 16) between PPI and non-PPI groups, but the ratio of gastrointestinal events had a higher tendency in non-PPI group compared with PPI group (1 vs. 17, P=0.08). In subgroup analysis of patients taking clopidogrel, or patients with acute coronary syndrome, there was no significant difference in the ratio of cardiovascular events (7 vs. 16, 6 vs. 17, NS). The non-PPI group had a tendency of an increased risk of gastrointestinal events compared with the PPI group (0 vs. 9, P=0.06; 1 vs. 7, P=0.14).
  
  
  CONCLUSIONS
  In contrast to the negative drug interaction of PPI reported elsewhere, in the present study the intake of PPI was not associated with an increased risk for adverse clinical outcomes in patients treated with stents.
authors: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
authors: Tadasuke
authors: T
authors: Chitose
authors: Seiji
authors: S
authors: Hokimoto
authors: Shuichi
authors: S
authors: Oshima
authors: Koichi
authors: K
authors: Nakao
authors: Kazuteru
authors: K
authors: Fujimoto
authors: Yuji
authors: Y
authors: Miyao
authors: Hideki
authors: H
authors: Shimomura
authors: Ryusuke
authors: R
authors: Tsunoda
authors: Hideki
authors: H
authors: Maruyama
authors: Toyoki
authors: T
authors: Hirose
authors: Koichiro
authors: K
authors: Yamamoto
authors: Michio
authors: M
authors: Mizobe
authors: Koichi
authors: K
authors: Kaikita
authors: Sunao
authors: S
authors: Nakamura
authors: Hisao
authors: H
authors: Ogawa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D044466:Asian People / Q000208:ethnology*; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003327:Coronary Disease / Q000208:ethnology* / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006356:Heartburn / Q000453:epidemiology; D006396:Hematemesis / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007564:Japan; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012042:Registries; D012189:Retrospective Studies; D015607:Stents; D020521:Stroke / Q000453:epidemiology; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin